Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Suominen Corporation October 1, 2026, at 3:00 p.m. (EEST) Suominen Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Charles Héaulmé Position: Chief Executive Officer Issuer: Suominen Oyj LEI: 743700Z1BNFYR9PRDF52 Notification type: INITIAL NOTIFICATION Reference number: 174870/6/6 ____________________________________________ Transaction date: 2026-09-30 Outside a trading venue Instrument type: SHARE ISIN: FI0009010862
Dama Solar is scheduled to enter commercial operations in H2 2028.
Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company's next phase of growth.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.